Neurocrine expects double-digit 2027 INGREZZA volume growth despite mid- to high single-digit net pricing headwinds

Neurocrine Q3 2026 earnings: record sales, raised INGREZZA guidance, and VYKAT XR safety updates.

CryptoAlerta — análise de criptomoedas e mercado em tempo real